Post-Test Intervention

OTHER2 trials

Sponsors

Abramson Cancer Center at Penn Medicine

Conditions

Cancer

Unknown Phase

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

CompletedNCT04353973

Abramson Cancer Center at Penn MedicineCancer

Start: 2020-08-17End: 2025-02-13Updated: 2025-07-29

eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer

RecruitingNCT05427240

Abramson Cancer Center at Penn MedicineCancer

Start: 2022-09-28End: 2026-07-01Target: 1000Updated: 2026-01-16

Related Papers

A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer (eREACH2): study protocol

BMC Cancer2026-07-31

A randomized non-inferiority trial of an eHealth delivery alternative for cancer genetic testing for hereditary cancer (eREACH2).

Journal of Clinical Oncology2026-05-27

An eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Patients With Metastatic Cancers: Protocol for a Randomized Trial

JMIR Research Protocols2025-06-304 citations

The ENGAGE study: a 3-arm randomized hybrid type 1 effectiveness and implementation study of an in-home, collaborative PCP model of remote telegenetic services to increase uptake of cancer genetic services in childhood cancer survivors.

2024-02-285 citations